Cargando…

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

BACKGROUND: Antibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This rejection type, which may occur at any time after transplantation, commonly presents as a continuum of microvascular inflammation (MVI) culminating in chronic tissue injury. While the clinical relevance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayer, Katharina A., Budde, Klemens, Halloran, Philip F., Doberer, Konstantin, Rostaing, Lionel, Eskandary, Farsad, Christamentl, Anna, Wahrmann, Markus, Regele, Heinz, Schranz, Sabine, Ely, Sarah, Firbas, Christa, Schörgenhofer, Christian, Kainz, Alexander, Loupy, Alexandre, Härtle, Stefan, Boxhammer, Rainer, Jilma, Bernd, Böhmig, Georg A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990453/ https://www.ncbi.nlm.nih.gov/pubmed/35395951 http://dx.doi.org/10.1186/s13063-022-06198-9

Ejemplares similares

Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial
por: Eskandary, Farsad, et al.
Publicado: (2019)

Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism
por: Mühlbacher, Jakob, et al.
Publicado: (2021)

The therapeutic challenge of late antibody‐mediated kidney allograft rejection
por: Böhmig, Georg A., et al.
Publicado: (2019)

Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10
por: Mayer, Katharina A., et al.
Publicado: (2022)

Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients
por: Mühlbacher, Jakob, et al.
Publicado: (2020)

Diagnostic value of donor‐derived cell‐free DNA to predict antibody‐mediated rejection in donor‐specific antibody‐positive renal allograft recipients
por: Mayer, Katharina A., et al.
Publicado: (2021)

Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009—Results from a Randomized First-in-Human Phase 1 Trial
por: Mühlbacher, Jakob, et al.
Publicado: (2017)

Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
por: Eskandary, Farsad, et al.
Publicado: (2014)

Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection
por: Mező, Blanka, et al.
Publicado: (2019)

Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection
por: Borski, Anita, et al.
Publicado: (2022)

Longitudinal assessment of HLA and MIC-A antibodies in uneventful pregnancies and pregnancies complicated by preeclampsia or gestational diabetes
por: Küssel, Lorenz, et al.
Publicado: (2017)

High-activity Classical and Alternative Complement Pathway Genotypes—Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival
por: Mező, Blanka, et al.
Publicado: (2020)

Effect of the Anti‐C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody–Induced Complement Activation—A Preclinical In Vitro Study
por: Wahrmann, M., et al.
Publicado: (2017)

Renal allograft DARCness in subclinical acute and chronic active ABMR
por: Kläger, Johannes, et al.
Publicado: (2021)

ABO-Incompatibility: Time to Challenge the Paradigm of Equivalence in Live-Donor Kidney Transplantation?
por: Eskandary, Farsad, et al.
Publicado: (2022)

Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation
por: Roufosse, Candice, et al.
Publicado: (2022)

Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome
por: Vietzen, Hannes, et al.
Publicado: (2022)

Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti–CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study
por: Rovin, Brad H., et al.
Publicado: (2022)

Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients—A prospective observational trial
por: Doberer, Konstantin, et al.
Publicado: (2020)

Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe
por: Rostaing, Lionel P. E., et al.
Publicado: (2023)

Relating Molecular T Cell–mediated Rejection Activity in Kidney Transplant Biopsies to Time and to Histologic Tubulitis and Atrophy-fibrosis
por: Madill-Thomsen, Katelynn S., et al.
Publicado: (2023)

Torque Teno Virus Load Is Associated With Subclinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial
por: Doberer, Konstantin, et al.
Publicado: (2021)

Molecular diagnosis of ABMR with or without donor‐specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes
por: Halloran, Philip F., et al.
Publicado: (2022)

Magnetic Resonance Imaging for Evaluation of Interstitial Fibrosis in Kidney Allografts
por: Beck-Tölly, Andrea, et al.
Publicado: (2020)

Stopping of Mycophenolic Acid in Kidney Transplant Recipients for 2 Weeks Peri-Vaccination Does Not Increase Response to SARS-CoV-2 Vaccination—A Non-randomized, Controlled Pilot Study
por: Regele, Florina, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2021)

Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step
por: Lachmann, Nils, et al.
Publicado: (2017)

High Titer Persistent Neutralizing Antibodies Induced by TSST-1 Variant Vaccine Against Toxic Shock Cytokine Storm
por: Roetzer, Andreas, et al.
Publicado: (2020)

Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation
por: Seron, Daniel, et al.
Publicado: (2022)

Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients
por: Strassl, Robert, et al.
Publicado: (2018)

Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers
por: Magyarics, Zoltan, et al.
Publicado: (2019)

Archetypal Analysis of Injury in Kidney Transplant Biopsies Identifies Two Classes of Early AKI
por: Halloran, Philip F., et al.
Publicado: (2022)

Determinants of the intercept and slope of glomerular filtration rate in recipients of a live donor kidney transplant
por: Hamböck, Martina, et al.
Publicado: (2020)

Levels of donor‐derived cell‐free DNA and chemokines in BK polyomavirus‐associated nephropathy
por: Mayer, Katharina A., et al.
Publicado: (2022)

Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid
por: Reindl-Schwaighofer, Roman, et al.
Publicado: (2022)

Surface Plasmon Resonance Analysis Shows an IgG-Isotype-Specific Defect in ABO Blood Group Antibody Formation in Patients with Common Variable Immunodeficiency
por: Fischer, Michael B., et al.
Publicado: (2015)

Micellar Curcumin: Pharmacokinetics and Effects on Inflammation Markers and PCSK‐9 Concentrations in Healthy Subjects in a Double‐Blind, Randomized, Active‐Controlled, Crossover Trial
por: Grafeneder, Juergen, et al.
Publicado: (2022)

Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection
por: Waiser, Johannes, et al.
Publicado: (2016)

Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients
por: Strassl, Robert, et al.
Publicado: (2019)

Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review
por: Cabezas, Lara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s4s4khope3aldbfo72qgml6lst